You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

CLINICAL TRIALS PROFILE FOR PIMAVANSERIN

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Pimavanserin

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00477672 ↗	A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	Completed	ACADIA Pharmaceuticals Inc.	Phase 3	2007-06-01	This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
NCT00550238 ↗	A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	Completed	ACADIA Pharmaceuticals Inc.	Phase 3	2007-07-01	To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.
NCT00658567 ↗	A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	Completed	ACADIA Pharmaceuticals Inc.	Phase 3	2008-03-01	This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
NCT01174004 ↗	A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis	Completed	ACADIA Pharmaceuticals Inc.	Phase 3	2010-07-01	The purpose of this study is to evaluate the safety and efficacy of 40 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).
NCT01518309 ↗	An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients	Completed	ACADIA Pharmaceuticals Inc.	Phase 2	2004-11-17	This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).
NCT02035553 ↗	A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis	Completed	ACADIA Pharmaceuticals Inc.	Phase 2	2013-11-01	This study will evaluate the safety and efficacy of pimavanserin 40 mg compared to placebo in patients with Alzheimer's disease psychosis.
NCT02762591 ↗	Expanded Access of Pimavanserin for Patients With PD Psychosis	Approved for marketing	ACADIA Pharmaceuticals Inc.		1969-12-31	The purpose of this program is to provide patients with PDP access to pimavanserin until the product receives marketing approval from the FDA and is commercially available.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Pimavanserin

Condition Name

Chart
Table

Condition Name for Pimavanserin
Intervention	Trials
Parkinson's Disease Psychosis	9
Schizophrenia	5
Adjunctive Treatment of Major Depressive Disorder	4
Parkinson Disease	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Pimavanserin
Intervention	Trials
Parkinson Disease	16
Psychotic Disorders	12
Mental Disorders	12
Disease	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Pimavanserin

Trials by Country

Map
Table

Trials by Country for Pimavanserin
Location	Trials
United States	350
Russian Federation	21
China	19
Ukraine	16
Canada	12
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Pimavanserin
Location	Trials
Texas	20
Florida	20
California	20
Ohio	17
New York	17
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Pimavanserin

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Pimavanserin
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	14
Phase 2/Phase 3	2
[disabled in preview]	16
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Pimavanserin
Clinical Trial Phase	Trials
Completed	15
Recruiting	10
Not yet recruiting	8
[disabled in preview]	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pimavanserin

Sponsor Name

Chart
Table

Sponsor Name for Pimavanserin
Sponsor	Trials
ACADIA Pharmaceuticals Inc.	31
Baylor College of Medicine	2
VA Office of Research and Development	2
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Pimavanserin
Sponsor	Trials
Industry	33
Other	22
U.S. Fed	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.